Charles Smith, MD
Internal Medicine · Charleston, SCNPI 1649222928
Payments from drug & device makers
Across 198 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$450
- Novo Nordisk$398
- Lilly USA, LLC$289
- GSK$256
- Amgen$202
- E.r. Squibb & Sons, L.L.C.$143
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 30 | $450 |
| Novo Nordisk | 31 | $398 |
| Lilly USA, LLC | 16 | $289 |
| GSK | 16 | $256 |
| Amgen | 12 | $202 |
| E.r. Squibb & Sons, L.L.C. | 10 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $137 |
| AstraZeneca | 10 | $127 |
| Abbott | 5 | $113 |
| Boehringer Ingelheim | 6 | $81 |
| Johnson & Johnson | 5 | $79 |
| Novartis | 4 | $65 |
| Bayer | 4 | $64 |
| AbbVie(2 entities) | 4 | $64 |
| Exact Sciences | 3 | $64 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 4 | $52 |
| Vital Connect, Inc | 1 | $51 |
| Astellas Pharma US Inc | 3 | $51 |
| Dexcom, Inc. | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $35 |
| Shire North American Group Inc | 2 | $34 |
| Boston Scientific | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $25 |
| Mylan Specialty L.p. | 2 | $24 |
| Hikma Pharmaceuticals USA | 2 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$3,117 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 114 | $155,414 |
| EliquisApixaban | 104 | $113,525 |
| OzempicSemaglutide | 87 | $112,186 |
| JardianceEmpagliflozin | 84 | $75,338 |
| TrulicityDulaglutide | 28 | $39,015 |
| RybelsusSemaglutide | 23 | $36,665 |
| MyrbetriqMirabegron | 34 | $30,477 |
| XareltoRivaroxaban | 15 | $20,853 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $18,308 |
| Repatha SureclickEvolocumab | 27 | $18,130 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $14,150 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $12,131 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $11,894 |
| FarxigaDapagliflozin Propanediol | 17 | $11,584 |
| Rosuvastatin Calcium | 563 | $9,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $289 | $194,429142 claims |
| Novo NordiskOzempic, Rybelsus | $398 | $148,851110 claims |
| PfizerEliquis | $450 | $113,525104 claims |
| Boehringer IngelheimJardiance | $81 | $75,33884 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $256 | $32,45859 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $30,47734 claims |
| Johnson & JohnsonXarelto | $79 | $20,85315 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $35 | $11,89412 claims |
| AstraZenecaFarxiga | $127 | $11,58417 claims |
| AbbVieSynthroid | $64 | $3,76954 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Charleston
- Jan BasileCharleston$278K
- James ThomasCharleston$154K
- John CleekCharleston$136K
- Shakaib RehmanCharleston$94K
- Leonard AlsfeldCharleston$91K
- Samuel Schumann IiiCharleston$48K
- Brett TomashitisCharleston$36K
- Scott SandsCharleston$25K
- Laura KinneyCharleston$20K
- Andrew SchreinerCharleston$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.